Ark Biosciences and KOLs Published a Review Paper on Antiviral Drug Resistance Across Chronic and Acute Infections
Antiviral therapy can lead to drug resistance, but multiple factors determine the frequency of drug resistance mutations and the clinical consequences. In this discussion paper, we consider the molecular factors contributing to antiviral drug resistance substitutions. The implications of resistance are considered for clinical trial endpoints and public health, as well as the requirements for therapeutic monitoring in clinical practice with acute viral infections.
know more >
Ark Biosciences to Present Efficacy Data on Novel Ziresovir at an International Conference
ArkBio to present efficacy data on its novel RSV F-protein inhibitor, Ziresovir (AK0529) at the 11th International RSV Symposium in Asheville, North Carolina, USA, 31st October – 4th November 2018
know more >